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Next generation sequencing technologies [1, 
2], increasing affordability, the ability to undertake 
high throughput large volume testing and advances in 
bioinformatics has made large scale population based 
genetic testing technically feasible. Coupled with a 
rapidly changing genomic landscape, improved genetic 
understanding of disease and increasing awareness, this 
offers a massive opportunity to apply this knowledge 
and technology on a broad population scale to make an 
important shift in healthcare towards disease prevention. 
Primary prevention and early detection strategies remain 
the cornerstone for reducing the burden of cancers in 
the population and this underpins the clinical utility of 
genetic testing for moderate/high penetrance cancer gene 
mutations.
The traditional approach to genetic-testing is based 
on an a priori threshold of mutation prevalence which 
is calculated using clinical-criteria centred mainly on 
family-history (FH). For BRCA-mutations this used 
to be set at 20% probability, which was subsequently 
reduced to around 10% probability. Approaches in use 
in clinical practice for this purpose range from assessing 
the FH through number of standardised clinical criteria 
to complex prediction models. This clinical-criteria/FH-
based approach has a number of limitations. It needs 
family members to be aware of the FH of cancer, and both 
members of the family and the GP/health professional 
consulted to understand the importance of this history 
and then make the referral to a genetics centre. We and 
others have shown this gate keeper approach misses over 
half the mutation carriers at risk. Small families, poor 
communication, paternal inheritance, limited awareness, 
etc. contribute to the poor performance of criteria based 
testing in ruling out the presence of a mutation. The 
current system is associated with huge underutilisation 
of genetic testing and delayed identification of unaffected 
individuals [3, 4]. Over 80% of eligible patients using 
National Cancer Comprehensive Network criteria in 
the USA have not been referred/undergone testing. We 
recently estimated that only 3% of the estimated BRCA-
carriers across Greater London (16-million population) 
had been identified and using forecasting models showed 
the current rates of testing are inadequate to detect all 
BRCA-carriers in the population [4]. A number of these 
limitations can be overcome by removing restrictions, 
broadening access and offering testing to everyone, i.e. 
population-testing. 
Population based BRCA-testing in the Jewish 
population has been thoroughly investigated in the 
UK Genetic Cancer Prediction through Population 
Screening (GCaPPS) randomised-controlled trial (RCT) 
(ISRCTN73338115) [5], as well as in Israeli [6] and 
Canadian [7] single-arm cohort studies. Data show that in 
the Jewish-population unselected BRCA-testing identifies 
>50% additional BRCA-carriers, is acceptable, feasible, 
can be undertaken in a community setting and does not 
adversely affect psychological well-being or quality-
of-life compared to FH-based testing, and has high 
satisfaction rates [5, 8]. Additionally such an approach is 
highly cost-effective for both UK and US health systems 
[9-11]. In fact it is cost-saving in most scenarios. There 
is thus strong evidence to support change in paradigm to 
population-based BRCA-testing in the Jewish community. 
However, these data cannot be directly extrapolated to the 
non-Jewish general population. 
Nevertheless, general (non-Jewish) population 
testing offers the opportunity to use genomics to maximise 
cancer prevention/early detection and reduce cancer 
burden on a much larger scale. Why should individuals in 
the family need to develop cancer before other unaffected 
individuals in the family can be identified? Additionally, 
the availability of panel germline testing now enables 
population testing to be undertaken for multiple cancer 
susceptibility genes but the genes included must have 
‘well-established’ clinical-utility. Surgical prevention is 
cost-effective [12, 13] for the newer moderate penetrance 
OC gene mutations RAD51C/RAD51D/BRIP1 (OC 
lifetime risks ~6-11%) and testing for these is now 
established in clinical practice [14]. PALB2 is a moderate-
risk gene with BC-risks [15] for which MRI/mammogram 
screening and risk-reducing mastectomy is available. In 
addition the Lynch Syndrome associated genes MLH1, 
MSH2 and MSH6 are also potential candidates that could 
become part of an extended population germline testing 
panel. 
We recently modelled population testing for 
multiple BC and OC gene mutations (BRCA1/BRCA2/
RAD51C/RAD51D/BRIP1/PALB2) compared to the 
traditional clinical-criteria/FH-based approach [16]. We 
showed that panel testing for multiple OC/BC genes was 
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more cost-effective than BRCA-testing alone. Critically, 
population based testing for BRCA1/BRCA2/RAD51C/
RAD51D/BRIP1/PALB2 was more cost-effective than 
any currently used clinical-criteria/family-history based 
strategy. The ICER (incremental cost-effectiveness 
ratio) was £21,599.96/QALY and $54,769.78/QALY for 
UK and US health systems, well below the thresholds 
of £30,000/QALY and $100,000/QALY in the UK and 
USA respectively. This amounts to 9.34 or 7.57 days 
life-expectancy gained (across the population). Robust 
sensitivity analyses (10,000 simulations on probabilistic 
sensitivity analysis) indicated that population testing 
is cost-effective and the preferred strategy in 84% 
simulations in the UK and 93% simulations in the USA 
models respectively. Such an approach could potentially 
prevent an additional 657/655 OC-cases and 2420/2386 
BC cases per million UK/USA women respectively. 
Extrapolating this across the population amounts to 
potentially 17505 and 65221 OC cases prevented in 
UK and USA women and 64493 and 237610 BC cases 
prevented in UK and USA women respectively. However, 
cost-effectiveness analysis, incurs assumptions, and 
further research is necessary to prospectively validate 
some key assumptions, such as, the surgical prevention 
uptake rates in those without a strong FH of cancer.
The feasibility of population based germline panel 
testing for OC gene mutations has been demonstrated in an 
ongoing pilot study in London [17]. The time has come to 
undertake large research studies to evaluate the impact of 
population based panel germline testing in an unselected 
non-Jewish general population. This includes impact on 
quality-of-life, psychological well-being, satisfaction 
and long-term health-behaviour and lifestyle. The best 
implementation model to deliver this approach also needs 
to be identified through robust evaluation and comparison 
with the current standard of care in well-designed trial(s). 
A key issue which will need resolving is a system for 
ongoing monitoring, reclassification (where needed) and 
management of VUS (variants of uncertain significance). 
Other matters that need tackling include increasing 
public/health professional awareness and education, 
delivery logistics, quality-control, call-recall mechanisms 
and expansion of downstream pathways of care. These 
steps are necessary for the health-system to achieve its 
maximum potential for reducing burden of disease now 
afforded through cancer screening and prevention.
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